Up to 50% of the patients with non-small cell lung cancer (NSCLC) have actionable genomic alterations (AGAs), driving the use of targeted therapies. Over the past decade, antibody-drug conjugates (ADCs) -combining a monoclonal antibody, linker, and potent cytotoxic drug to selectively target cancer cells- have emerged as a promising treatment option. This article reviews the available evidence regarding the efficacy and safety of ADCs in patients with NSCLC harbouring AGAs.
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
